Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor-Reference-Cited by-同舟云学术

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Published:2011-12-21 Issue:2 Volume:11 Page:317-328
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Maira Sauveur-Michel,Pecchi Sabina,Huang Alan,Burger Matthew,Knapp Mark,Sterker Dario,Schnell Christian,Guthy Daniel,Nagel Tobi,Wiesmann Marion,Brachmann Saskia,Fritsch Christine,Dorsch Marion,Chène Patrick,Shoemaker Kevin,De Pover Alain,Menezes Daniel,Martiny-Baron Georg,Fabbro Doriano,Wilson Christopher J.,Schlegel Robert,Hofmann Francesco,García-Echeverría Carlos,Sellers William R.,Voliva Charles F.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 468 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From lab to clinic: The discovery and optimization journey of PI3K inhibitors;European Journal of Medicinal Chemistry;2024-11

2. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

3. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

4. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

5. A meta-analysis of the risk of adverse cardiovascular events in patients with cancer treated with inhibitors of the PI3K/AKT/mTOR signaling pathway;2024-08-09